The aim of this study was to evaluate the possibility of cross-reactivity between ketoprofen, fenofibrate and benzophenones because of their structural similarities. Seven patients presenting photodermatitis from ketoprofen underwent patch and photopatch tests. Ketoprofen, fenofibrate, benzophenone 3, benzophenone 10, benzophenone 4, personal medications and topical creams were tested. All patients had positive patch or photopatch tests to ketoprofen and fenofibrate, four patients had positive UVA photopatch tests to benzophenone 3, and two to benzophenone 10. Patients presenting photosensitization to ketoprofen may also have cross-reactivity to fenofibrate and some benzophenones.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0781.1997.tb00123.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fenofibrate Inhibits LPS and Zymosan-induced Inflammatory Responses through Sonic Hedgehog in IMG Cells.
Curr Mol Pharmacol
January 2025
Department of Biochemistry, School of Medicine, China Medical University, Taichung, Taiwan.
Background: Neuroinflammatory responses are strongly associated with the pathogenesis of progressive neurodegenerative conditions and mood disorders. Modulating microglial activation is a potential strategy for developing protective treatments for central nervous system (CNS)-related diseases. Fibrates, widely used in clinical practice as cholesterol-lowering medications, exhibit numerous biological activities, such as anticancer and antiinflammatory activities.
View Article and Find Full Text PDFSignificantly improving the solubility and anti-inflammatory activity of fenofibric acid with native and methyl-substituted beta-cyclodextrins via complexation.
Sci Rep
January 2025
School of Chemical Engineering, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
The solubility of commonly used anti-inflammatory drugs has become a significant concern in contemporary medicine. Furthermore, inflammatory arthritis stands out as the most prevalent chronic inflammatory disease globally. The disease's pathology is characterized by heightened inflammation and oxidative stress, culminating in chronic pain and the loss of joint functionality.
View Article and Find Full Text PDFPPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.
Hepatol Commun
January 2025
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
Article Synopsis
- Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are liver diseases that damage bile ducts, leading to bile accumulation, liver injury, and increased risk of liver failure; current treatments are limited, especially for PSC.
- Ursodeoxycholic acid is the first-line treatment for PBC, but many patients do not respond fully, indicating a need for better therapies; pruritus (itching) is a common and severe symptom due to cholestasis that is often inadequately treated.
- The review examines the use of PPAR agonists, a type of medication that targets liver metabolism, as potential second-line treatments for PBC and PSC, highlighting recent FDA approvals for
Reduction of Alcohol-Dependent Lung Pathological Features in Rats Treated with Fenofibrate.
Int J Mol Sci
November 2024
Instituto de Ciencias Biomédicas (ICB), Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago 8910132, Chile.
Alcohol use disorder (AUD) is a public health problem characterized by a marked increment in systemic inflammation. In the last few years, it has been described as the role of alcohol in neuroinflammation affecting some aspects of neuronal function. Interestingly, inflammation is reduced with fenofibrate treatment, a PPARα agonist used to treat dyslipidemia.
View Article and Find Full Text PDFPrecise Carrier-Free Pt(IV)-Nanobombs for Apoptosis/Ferroptosis Synergistic Tumor Therapy: A New Effective Method to Obtain Good Chemotherapy and Low Toxicity.
J Med Chem
January 2025
Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmacy, Hebei University, Baoding 071002, Hebei, P. R. China.
The emerged apoptosis/ferroptosis synergistic platinum-based therapy has attracted a lot of attention but is far from clinic use due to high systemic toxicity. Herein, a series of novel precise carrier-free self-assembled platinum(IV) nanoparticles with lipid regulation effect named FSPNPs (NPs-NPs) were constructed via connecting fenofibrate acid (FA) to cisplatin or oxaliplatin-derived platinum(IV)-intermediates with disulfide bonds. FSPNPs can be stimulated by high-glutathione/ascorbic acid and acidity environment to produce an "explosion-like" cascade release process.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!